Sarepta Therapeutics, Inc. (SRPT) Stock Price & Analysis

Sarepta Therapeutics, Inc. (SRPT) closed at USD 19.23 on Thursday, October 29, 2026, down 0.47% on the day. The US market is currently closed (after-hours); this is not a live price.

The prior close was USD 19.32; the Oct 29, 2026 session ranged USD 18.96–19.68 on volume of 1,185,248 shares. Market capitalization is $2.03B, with a 52-week range of USD 14.68–24.68 (NMS). Source: Nexqual, retrieved October 29, 2026 at 22:04 UTC.

Also available as compact Markdown for AI agents: nexqual.com/SRPT.md

Key facts (SRPT)

• Last four reported quarters (through Jun 30, 2026): revenue $1.97B, net income -$137M (-6.9% margin), free cash flow $81.8M (SEC filings).
• Analysts: Hold (mean 3.00 on a 1–5 scale) (24 analysts), mean target USD 21.64 (range 5–38).
• Total return with dividends: 1Y -17.3% vs S&P 500 +14.4%; 5Y -75.7% vs S&P 500 +79.1%.
• Next earnings: 2026-11-05, EPS estimate USD 0.36, revenue estimate $350M. All companies reporting that day: https://nexqual.com/earnings/2026-11-05
• Dividend: SRPT paid no cash dividend in the last five years.
• Short interest: 25.34% of float (as of 2026-10-15), 7.8 days to cover.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (SRPT)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (SRPT)

P/S 1.0x · EV/Sales 1.1x · P/FCF 24.8x · P/B 1.3x · FCF yield 4.03% · Earnings yield -6.73% · Net debt $59.1M · EV $2.09B

P/E at fiscal year-ends: Dec 2024 55.8x.

Analysts (SRPT)

Consensus Hold (mean 3.00 on a 1–5 scale), 24 analysts; mean target USD 21.64 (low 5, high 38).

Rating changes, last 120 days:

Total return (dividends reinvested) (SRPT)

Dividends (SRPT)

SRPT paid no cash dividend in the last five years.

Short interest (SRPT)

22,330,342 shares sold short, 25.34% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 25,434,681 shares (-12.2%). Days to cover: 7.8 (short shares ÷ average daily volume).

SRPT earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

SRPT revenue by product line (quarter ended Jun 30, 2026)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

SRPT customer concentration

In the period ended Jun 30, 2026, 3 direct customers each accounted for at least 10% (35%, 22%, 10%) of revenue, per the company's 10-Q filed Aug 5, 2026. The company does not name them.

SRPT analyst estimates and revisions

SRPT options: expected move

Options price a move of about ±10.9% (±$2.10) by Nov 6, 2026, which includes earnings on Nov 5, 2026. Over the last 8 reports the stock moved ±10.7% on average.

30-day implied volatility 95.1% vs 56.7% realized over the last 30 trading days. Put/call ratio (volume) 1.68. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 29, 2026 at 22:04 UTC)

Technical Analysis (SRPT)

Nexqual's technical model rates SRPT "BUY" based on 4 bullish and 2 bearish signals across 127 daily candles, as of October 29, 2026 at 22:04 UTC.

Analyst Ratings (SRPT)

Wall Street analysts rate SRPT "Hold" based on 24 analysts, with a mean price target of USD 21.64 (range USD 5–38), per Nexqual as of October 29, 2026 at 22:04 UTC.

Earnings (SRPT)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 22:04 UTC.

Financials & Fundamentals (SRPT)

Source: Nexqual, October 29, 2026 at 22:04 UTC.

Financial Health Score (SRPT)

Nexqual rates Sarepta Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of October 29, 2026 at 22:04 UTC.

Ownership (SRPT)

Source: Nexqual, October 29, 2026 at 22:04 UTC.

Leadership (SRPT)

Sarepta Therapeutics, Inc. is led by Michael E. Severino, CEO & Director, per Nexqual as of October 29, 2026 at 22:04 UTC.

Major Backers & Investors (SRPT)

Notable institutional backers of Sarepta Therapeutics, Inc. include First TRT Exch-Trd Fd.-First TRT NYSE Arca Biotechnology Index Fd., Two Sigma Investments, LP, First Trust Advisors LP, according to Nexqual as of October 29, 2026 at 22:04 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 29, 2026 at 22:04 UTC.

From Sarepta Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-02)

Key Strengths & Strategy (as disclosed to the SEC)

• Applying our proprietary, differentiated and innovative technologies, and through collaborations with our strategic partners, we have developed multiple approved products for the treatment of Duchenne muscular dystrophy ("Duchenne") and are developing potential therapeutic candidates for a broad range of diseases and disorders, including Duchenne and LGMD.
• The chart below summarizes the status of our programs, including those with our strategic partners: We have developed proprietary state-of-the-art Chemistry, Manufacturing and Controls ("CMC") capabilities that allow manufacturing and testing of our products and product candidates to support both clinical development and commercialization.
• We believe that our proprietary technology platforms and collaborations can be used to develop novel pharmaceutical products to treat a broad range of diseases and address key currently-unmet medical needs.
• The original PMO structure and variations of this structure that are so-called PMO-based (collectively "PMO-based") are central to our proprietary chemistry platform.

Partnerships

• In April 2013, we entered into an agreement with UWA under which an existing exclusive license agreement between the two parties was amended and restated and, in June 2016, we entered into the first amendment to the license agreement (the "UWA License Agreement").
• Consequently, the Company entered into an agreement with Arrowhead to transfer approximately 2.7 million shares of Arrowhead common stock, valued at approximately $50.0 million.

Legal & Regulatory Risks (Item 1A, quoted)

• Our products or product candidates may cause undesirable side effects, result in new safety signals or have other properties that could delay or prevent regulatory approval of product candidates, limit the commercial potential or result in significant negative consequences following any potential marketing approval.
• We may not have the resources required to meet regulatory requirements and successfully navigate what is generally a lengthy, expensive and extensive approval process for commercialization of drug product candidates.
• Our commercial products and product candidates in development—including our PMOs, gene therapies, and siRNA therapies—are novel and complex technologies that are or may be difficult to manufacture. The novelty of these therapies, in addition to the regulatory oversight and review they face, may lead to production issues or volatility in both supply and demand.
• The third parties we use in the manufacturing process for our products and product candidates may fail to comply with cGMP regulations.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 22:04 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt